Literature DB >> 193526

On the rise in low density and high density lipoproteins in response to the treatment of hypertriglyceridaemias in type IV and type V hyperlipoproteinaemias.

L A Carlson, G Olsson, D Ballantyne.   

Abstract

In Type V hyperlipoproteinaemia the concentration of LDL and HDL cholesterol is low. When the hypertriglyceridaemia is normalized, either by diet or micotinic acid, both LDL and HDL increase. In Type IV hyperlipoproteinaemia both LDL and HDL cholesterol decrease with increasing VLDL levels. During treatment of Type IV the change in LDL cholesterol is linearly related to the pretreatment LDL concentration so that higher LDL levels will fall and the lower will rise. HDL levels will also rise. The fall in VLDL during treatment is rapid and the rise in LDL also occurs rapidly indicating a relationship between these two reciprocal changes. HDL cholesterol, however, however, remains constant some time after VLDL has reached its lowest level and the rise occurs later indicating another mechanism than for LDL. These changes in the three major lipoprotein classes deserve clinical attention. While both the fall in VLDL and the rise in HDL may be benefical from the point of view of atherosclerosis the rise in LDL may be harmful. These is at present no way to evaluate the effect of these complex changes. However, these findings stress the imporance of considering changes in lipoprotein levels and not only in total serum triglycerides and cholesterol during treatment of hyperlipoproteinaemia.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 193526     DOI: 10.1016/0021-9150(77)90127-7

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.

Authors:  L Kłosiewicz-Latoszek; W B Szostak
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Specific lipid lowering therapy in the management of diabetes.

Authors:  P N Durrington
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

3.  Metabolic fate of chylomicron phospholipids and apoproteins in the rat.

Authors:  A R Tall; P H Green; R M Glickman; J W Riley
Journal:  J Clin Invest       Date:  1979-10       Impact factor: 14.808

4.  Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism.

Authors:  J Shepherd; C J Packard; J R Patsch; A M Gotto; O D Taunton
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

5.  Cholesteryl ester and triacylglycerol fatty acids in type V hyperlipidemia.

Authors:  R G Jensen; R M Clark; S A Gerrior; M B Fey; A M Gotto
Journal:  Lipids       Date:  1979-07       Impact factor: 1.880

6.  Mechanism of action of gemfibrozil on lipoprotein metabolism.

Authors:  K Saku; P S Gartside; B A Hynd; M L Kashyap
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

7.  [Bezafibrate in primary hyperlipidemias (author's transl)].

Authors:  J G Wechsler; V Hutt; H U Klör; G Bode; H Ditschuneit
Journal:  Klin Wochenschr       Date:  1982-01-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.